Sep 7, 2016 7:39am EDT Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Sep 6, 2016 7:00am EDT Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update
Aug 29, 2016 7:00am EDT Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder
Aug 15, 2016 7:00am EDT Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium
Aug 8, 2016 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update
Jul 26, 2016 8:00am EDT Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
Jul 12, 2016 4:30pm EDT Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Jul 7, 2016 4:05pm EDT Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jun 17, 2016 8:00am EDT Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
